Symbols / ONCT
ONCT Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-11-06 16:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- From Nasdaq to Dark: What's Next for Oncternal After March 2025 Delisting? - Stock Titan Fri, 07 Mar 2025 08
- Same ROR1 antibody, different outcome | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline Wed, 02 Jul 2025 07
- Oncternal shares to be delisted from Nasdaq - Investing.com Mon, 25 Nov 2024 08
- Oncternal stock crashes by 60% as it lays off staff and scraps trials - Pharmaceutical Technology Fri, 13 Sep 2024 07
- Man killed in wrong-way and head-on CT crash; four others seriously injured - Hartford Courant Sun, 02 Nov 2025 07
- Oncternal folds all clinical trials after lackluster data drop, patient death - Fierce Biotech hu, 12 Sep 2024 07
- Leidos (NYSE: LDOS), Quadridox Plan AI CT XRDI Baggage Screening Trial in 2026 - Stock Titan ue, 25 Nov 2025 08
- Oncternal Therapeutics (ONCT) Stock Price, News & Analysis - MarketBeat Sat, 25 Jul 2020 16
- ONCT-534 Gains FDA Fast Track Designation in mCRPC - Targeted Oncology Fri, 27 Oct 2023 07
- 10 Underperforming Stocks Insiders are Buying - Yahoo Finance Wed, 10 Apr 2024 07
- StockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt Investors - GEN - Genetic Engineering and Biotechnology News Mon, 16 Sep 2024 07
- GTx merges with biotech firm, new HQ to be based in San Diego - The Business Journals hu, 07 Mar 2019 08
- Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives - GlobeNewswire hu, 12 Sep 2024 07
- The pullback from ROR1 and TILs continues | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline Fri, 25 Oct 2024 07
- David Moss replaces Philip Webster on CT UK High Income - Citywire Fri, 14 Jul 2023 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ONCT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|